[{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Shanghai Municipal Science and Technology Commission | Shanghai Jiaotong University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Shanghai Municipal Science and Technology Commission | Shanghai Jiaotong University School of Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Mental Health Center \/ Shanghai Municipal Science and Technology Commission | Shanghai Jiaotong University School of Medicine"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Shanghai Jiaotong University School of Medicine | Chinese Academy of Sciences | Shanxi Medical University | Central South University | Second Military Medical University | Peking University Sixth Hospital | First Affiliated Hospital Xi'an Jiaotong Univers","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Shanghai Jiaotong University School of Medicine | Chinese Academy of Sciences | Shanxi Medical University | Central South University | Second Military Medical University | Peking University Sixth Hospital | First Affiliated Hospital Xi'an Jiaotong Univers","highestDevelopmentStatusID":"11","companyTruncated":"Shanghai Mental Health Center \/ Shanghai Jiaotong University School of Medicine | Chinese Academy of Sciences | Shanxi Medical University | Central South University | Second Military Medical University | Peking University Sixth Hospital | First Affiliated Hospital Xi'an Jiaotong Univers"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Peking University Sixth Hospital | Shanghai Tongji Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Peking University Sixth Hospital | Shanghai Tongji Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Mental Health Center \/ Peking University Sixth Hospital | Shanghai Tongji Hospital"},{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Torrent Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Torrent Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Torrent Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Torrent Pharmaceuticals Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Torrent Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Torrent Pharmaceuticals Limited \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Torrent Pharmaceuticals Limited \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Harvard Medical School (HMS and HSDM)","sponsor":"Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harvard Medical School (HMS and HSDM)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Medical School (HMS and HSDM) \/ Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men","highestDevelopmentStatusID":"10","companyTruncated":"Harvard Medical School (HMS and HSDM) \/ Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men"},{"orgOrder":0,"company":"Harvard Medical School (HMS and HSDM)","sponsor":"National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harvard Medical School (HMS and HSDM)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Medical School (HMS and HSDM) \/ National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal","highestDevelopmentStatusID":"10","companyTruncated":"Harvard Medical School (HMS and HSDM) \/ National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Saptalis pharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Saptalis pharm","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Saptalis pharm \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Saptalis pharm \/ Undisclosed"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"SERT","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"INDIA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Marksans Pharma \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Marksans Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"University of British Columbia | Sunnybrook Health Sciences Centre | University of Calgary | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview Health Centre Foundation | Memorial University of Newfoundland | Applied Health Research Cen","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ University of British Columbia | Sunnybrook Health Sciences Centre | University of Calgary | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview Health Centre Foundation | Memorial University of Newfoundland | Applied Health Research Cen","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ University of British Columbia | Sunnybrook Health Sciences Centre | University of Calgary | Dalhousie University | Parkwood Hospital, London, Ontario | Riverview Health Centre Foundation | Memorial University of Newfoundland | Applied Health Research Cen"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"ANI Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","highestDevelopmentStatusID":"8","companyTruncated":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","highestDevelopmentStatusID":"8","companyTruncated":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline"}]
Find Clinical Drug Pipeline Developments & Deals for Zedprex
Details :
Fluoxetine hydrochloride, is an antidepressant of the SSRIs class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder, bulimia nervosa, etc.
Details :
Fluoxetine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
Fluoxetine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
Fluoxetine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Depressive Disorder.
Sponsor :
National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal
Details :
Fluoxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depression.
Sponsor :
National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal
Details :
Fluoxetine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Stress Disorders, Post-Traumatic.
Sponsor :
Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men
Details :
Fluoxetine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depression.
Sponsor :
Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men
Details :
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It is indicated for both acute and maintenance treatment of MDD, OCD, and bulimia nervosa; however, it is only indicated for acute treatment of ...
Reset All
Synergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.
